29 results about "Cytarabine" patented technology

The invention discloses a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia and application, and relates to the technical field of biomedicine. The invention provides a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia. The combined pharmaceutical composition comprises vincristine and cytarabine or pharmaceutically acceptable salts and solvates of the vincristine and the cytarabine. According to the vincristine and cytarabine combined pharmaceutical composition, the apoptosis level of acute myelogenous leukemia cells can be remarkably improved, and compared with single-drug treatment, the vincristine and cytarabine combined pharmaceutical composition has higher anti-tumor efficacy; vincristine interferes or blocks a cell senescence state induced by cytarabine through a microtubule destruction effect, so that the problem of drug insensitivity caused by cell senescence is solved, and drug resistance caused by cell senescence is effectively reversed.

Compounds of the formula Iwherein X is a bond or —CH2, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine resistance and / or over 60 years of age.

The invention discloses a cytarabine syndrome risk prediction model, a training method thereof and a system adopting the same. The model training method comprises the following steps: constructing an artificial intelligence model; wherein the input of the artificial intelligence model comprises the weight and the heating duration of the to-be-evaluated object; the output of the artificial intelligence model is the risk probability that the to-be-evaluated object belongs to the cytarabine syndrome fever; large sample data are adopted to train the artificial intelligence model, cases with fever of the cytarabine syndrome are positive samples, and other fever cases are negative samples. According to the present invention, the identification standard of the cytarabine syndrome fever and the infected fever is established, and the risk probability of the cytarabine syndrome of the object to be evaluated can be evaluated by analyzing the difference of the two detection results in the laboratory, such that the unreasonable use of the antibacterial agent is reduced, the medical cost is reduced, and the drug resistance risk of the antibacterial agent is reduced.

The present invention relates to the use of cytarabine, a mitochondrial metabolism inhibitor and an agent that downregulates the expression or activity of CDA in the treatment of cancer.

The application relates to a pharmaceutical cocrystal of cytarabine and 5-fluorouracil and a preparation method thereof, and relates to the technical field of pharmaceutical cocrystals. The pharmaceutical cocrystal is composed of one cytarabine molecule and one 5-fluorouracil molecule as a basic structural unit, and has a chemical formula of [C9H 13 N3O5.C4H3N2O2F]; the pharmaceutical cocrystal belongs to an orthorhombic system and has a space group of P212121. The pharmaceutical cocrystal prepared by a solvent evaporation method and a cooling method improves the permeability of cytarabine, appropriately reduces the solubility of cytarabine, and significantly improves the antitumor activity of cytarabine; through the complementary advantages of the properties and the pharmacodynamic effects of two components, the synergistic antitumor effects of cytarabine and 5-fluorouracil are realized, and a new idea is provided for developing synergistic antitumor pharmaceutical cocrystals. The pharmaceutical cocrystal can keep the skeleton structure of the crystal unchanged after long-term placement at room temperature, the preparation method is simple and easy to implement, the cost is low, and the pharmaceutical cocrystal is convenient for large-scale production.

The invention belongs to the technical field of veterinary drugs, and particularly relates to novel application of monomeric compounds, in particular to application of nucleotide analogues in preparation of drugs for preventing and / or treating diseases caused by bovine nodular skin disease viruses. Iodine glycoside, non-auridine, cytarabine and vidarabine are all monomeric compounds and belong to nucleotide analogues. It is found for the first time that iodoglycoside, non-aurine glycoside, cytarabine and vidarabine can inhibit bovine nodular skin disease virus replication in a safe concentration range in a dose-dependent mode. The iodoglycoside, the non-aurine glycoside, the cytarabine and the vidarabine have low cytotoxicity, can efficiently inhibit the bovine nodular dermatosis virus, and have a good application prospect in the aspect of preventing or treating the bovine nodular dermatosis.

The application provides an application of a TRIM44 expression inhibitor in preparation of a cytarabine-resistant leukemia drug, and belongs to the technical field of bioengineering.The application provides the application of the TRIM44 expression inhibitor in preparation of the cytarabine-resistant leukemia drug.In the application, a key gene TRIM44 affecting AML drug resistance is identified by analyzing a single cell transcriptome data set, the expression of the TRIM44 can be lowered by using sinomenine, the function of regulatory T cells (T-reg cells) is inhibited, the sensitivity of AML cells to a chemotherapy drug is enhanced, a good synergistic treatment effect with cytarabine is shown, the cytarabine resistance of leukemia is reversed, and a new target site and a molecular marker are provided for predicting and improving the treatment effect of patients in clinic.

Novel cytotoxic fluoropyrimidine polymers for treating cancer (e.g., colorectal cancer (CRC)) in a subject (e.g., a subject having cancer) are nucleic acid molecules including 5-fluoro-2′deoxyuridine monophosphate (FdUMP)[10] having a polyethylene glycol (PEG) spacer appended to the 5′ terminus and a cytarabine (AraC) nucleotide appended to 3′termius. These novel cytotoxic fluoropyrimidine polymers may be used in compositions, kits and methods for treating advanced and high-risk cancers, including CRC.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.

This invention belongs to the field of biopharmaceuticals and specifically discloses the preparation and application of a compound formulation of Hedyotis diffusa (5-30 parts), Scutellaria barbata (3-10 parts), Houttuynia cordata (3-6 parts), Ganoderma lucidum (2-4 parts), and astaxanthin for adjuvant tumor treatment. This compound is prepared by gradient decoction, nanoemulsification, and synergistic combination of ingredients, including Hedyotis diffusa (5-30 parts), Scutellaria barbata (3-10 parts), Houttuynia cordata (3-6 parts), Ganoderma lucidum (2-4 parts), and astaxanthin (0.5-1 parts). The combination of gradient temperature-controlled decoction and nanoemulsification (particle size 50-200 nm) significantly improves the bioavailability of heat-sensitive components (such as astaxanthin), allowing for the design of various dosage forms (tablets, capsules, and pills) to meet diverse clinical needs. Animal models have demonstrated that this compound enhances the efficacy of cytarabine and cisplatin while reducing chemotherapy toxicity (resumption of ALT / AST levels to normal). This invention combines multi-target anti-tumor and immunomodulatory properties with dosage form stability, providing an innovative solution for adjuvant tumor treatment.

This invention relates to the use of cytarabine, mitochondrial metabolism inhibitors, and agents that downregulate the expression or activity of CDA in the treatment of cancer.

The invention discloses an application of curcumin in improving puberty male reproductive capacity damage caused by chemotherapeutic drugs. Aiming at the problems of testicular germ cell quantity reduction, oxidative stress injury, long-term fertility damage and the like caused by cytosine arabinoside chemotherapy, curcumin is applied while or before the cytosine arabinoside is applied. The application is realized through combined administration or a pharmaceutical composition containing curcumin and cytarabine. Experiments show that the scheme can effectively relieve testicular tissue form damage, reduce germ cell apoptosis and antagonize oxidative stress, and significantly improve the sperm quality of adult individuals. The invention provides a new potential strategy for synchronously protecting the reproductive function of a clinical child tumor patient during chemotherapy.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.

The utility model relates to dissolving equipment for cytarabine and daunorubicin compound lipidosome, which belongs to the technical field of medicine processing equipment and comprises a base, a connecting frame is mounted at the top of the base, a dissolving bin is mounted on one side, close to the center of the base, of the connecting frame, and a leakage bin is fixedly connected to the bottom of the dissolving bin. A dissolving tank is mounted in the dissolving bin, and a heater is mounted on the inner wall of the dissolving bin; a stirring mechanism for increasing the dissolving speed is mounted in the dissolving tank. The lipid dissolving device has the beneficial effects that through the arrangement of the stirring mechanism, the arc-shaped stirring paddle can be driven to rotate through the rotating motor and the rotating shaft, and lipid in the dissolving tank is stirred through the arc-shaped stirring paddle, so that the dissolving speed is increased, and meanwhile, one side of the arc-shaped stirring paddle is attached to the inner wall of the dissolving tank, so that the lipid dissolving effect is improved. The leakage holes can be prevented from being blocked by lipid, and it is ensured that dissolved liquid is smoothly discharged out of the dissolving tank.

The utility model relates to an emulsifying and mixing device for cytarabine and daunorubicin compound lipidosome, which belongs to the technical field of mixing devices and comprises a support frame, a support plate is fixedly connected to the inner wall of the support frame, a mixing tank is fixedly connected to the inside of the support plate, a sealing cover is connected to the upper end face of the mixing tank in an attached manner, and the sealing cover is fixedly connected to the upper end face of the mixing tank. A driving shaft is rotationally connected to the center of the interior of the sealing cover, and a stirring rod is fixedly connected to the outer wall of the driving shaft. The cytarabine and daunorubicin mixing tank has the beneficial effects that the turning plate rotates in the vertical direction at the bottom of the mixing tank, so that the material accumulation at the bottom of the mixing tank can be broken, the deposition and layering of the material at the bottom are effectively prevented, the uniform distribution of cytarabine and daunorubicin in the mixing process is ensured, and the mixing effect and the product quality are improved; and the material at the bottom can be turned upwards to be fully mixed with the material at the upper layer, so that the mixing process is accelerated, the mixing is more uniform, and the mixing efficiency is improved.

The invention provides application of the cytarabine combined immune checkpoint inhibitor in glioma treatment, experiments prove that the cytarabine combined immune checkpoint inhibitor has a synergistic effect on glioma treatment, and the anti-tumor effect of the cytarabine can be enhanced by the cytarabine combined immune checkpoint inhibitor; the lifetime of the mouse is obviously prolonged, and a new strategy is provided for treating glioma.

The present invention provides the use of a traditional Chinese medicine monomer, rhamnosine, or a solvate, hydrate, or salt thereof, in the preparation of a drug for treating or alleviating leukemia. The present invention explores the anti-tumor activity of rhamnosine from multiple levels, including in vitro and in vivo levels. Experiments have shown that the traditional Chinese medicine monomer, rhamnosine, can inhibit the proliferation of leukemia cell lines, induce cell apoptosis, and enhance the effect of cytarabine in inhibiting leukemia; in vivo, rhamnosine can inhibit the growth of leukemia subcutaneous transplanted tumors and prolong the survival of tumor-bearing mice. Further experiments revealed the biological mechanism by which rhamnosine inhibits leukemia proliferation and promotes apoptosis by regulating the PI3K‑AKT signaling pathway, indicating that it has certain prospects in the treatment of leukemia.

The invention discloses application of brutinib and a combined pharmaceutical composition thereof in treatment of leukemia, and the leukemia comprises acute myelogenous leukemia, chronic myelogenous leukemia, T acute lymphoblastic leukemia and B acute lymphoblastic leukemia. The invention creatively finds that the brutinib has a remarkable synergistic effect on treatment of the leukemia when being combined with the vinca, the cytarabine or the daunorubicin for use, and a brand new drug combination scheme provided by the invention provides a more effective drug combination choice for treatment of the leukemia, and is expected to improve the treatment effect of patients with the leukemia.

The present invention relates to the field of bioengineering technology, and particularly relates to the application of a ZBED1 expression inhibitor in the preparation of drugs for treating cytarabine-resistant leukemia. The present invention provides the application of a ZBED1 expression inhibitor in the preparation of drugs for treating cytarabine-resistant leukemia, and the drugs for treating cytarabine-resistant leukemia include a ZBED1 expression inhibitor. The present invention first establishes the key role of ZBED1 in leukemia drug resistance, and discovers the active ingredient of traditional Chinese medicine diosgenin that selectively inhibits the function of ZBED1. This ingredient can not only act synergistically with cytarabine to reverse the cytarabine resistance of leukemia, but also provide a new target site and molecular marker for clinically predicting and improving the treatment effect of patients. This innovative strategy brings new hope for leukemia treatment, especially in the problem of cytarabine resistance, providing a more effective solution.

The invention belongs to the field of biological medicines, and particularly discloses preparation and application of a hedyotis diffusa, sculellaria barbata, lucid ganoderma, houttuynia cordata and astaxanthin compound preparation for adjuvant therapy of tumors. The compound preparation is prepared from the following raw materials in parts by weight: 5-30 parts of oldenlandia diffusa, 3-10 parts of sculellaria barbata, 3-6 parts of houttuynia cordata, 2-4 parts of lucid ganoderma, 0.5-1 part of astaxanthin and the like through gradient decoction, nano emulsification and component synergistic compatibility. The bioavailability of thermosensitive components (such as astaxanthin) is remarkably improved by combining gradient temperature control decoction with a nano emulsification technology (the particle size is 50-200 nm), and various dosage forms (tablets, capsules and pills) are designed to meet different clinical requirements. In-vitro experiments show that the IC50 on HepG2 liver cancer cells is as low as 12.5 mu g / mL, and animal models confirm that the compound can enhance the curative effect of cytarabine and cis-platinum and reduce chemotherapy toxicity (ALT / AST is recovered to a normal level) at the same time. According to the invention, multi-target anti-tumor, immunoregulation and dosage form stability are integrated, and an innovative solution is provided for tumor adjuvant therapy.

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Pharmaceutical compositions comprising oil as a vehicle, a suspending agent, and a surfactant are disclosed to be used in conjunction with active pharmaceutical ingredients which are water soluble or insoluble, or which are sensitive to water but insoluble in oil. Such active pharmaceutical ingredients may include temozolomide, lenalidomide, Oxaliplatin, Cisplatin, Carboplatin, 5-fluorouracil, irinotecan, topotecan, cyclophosphamide, doxorubicin, vincristine, vinblastine, Melphalan, Chlorambucil, Dacarbazine, Daunorubicin, Epirubicin, Mitoxantrone, Etoposide, Teniposide, Azacitidine, Cytarabine, Gemcitabine, vinoralbine, Pemetrexed, a derivative thereof, or a combination thereof. The pharmaceutical compositions may be administered as an oral suspension. Other embodiments are directed towards methods of using and methods of making such formulations.

The invention relates to the technical field of animal cell culture, in particular to a method for separating, culturing and purifying olfactory bulb and olfactory ensheathing cells. The method specifically relates to the steps of isolated culture and purification, and a differential adhesion method, a cytarabine purification method and a serum-free culture purification method are combined in the purification step, so that the olfactory ensheathing cells with high purity and high cell viability are obtained.

The present invention discloses a co-loaded cytarabine and venetoclax nano-drug delivery system and its preparation method and application, belonging to the field of medical technology. The co-loaded cytarabine and venetoclax nano-drug delivery system is composed of human serum albumin, cytarabine derivatives and venetoclax. First, cytarabine is modified, then the disulfide bonds in the albumin are broken with a reducing agent, and finally, the cytarabine derivatives and venetoclax are loaded simultaneously to prepare the co-loaded cytarabine and venetoclax nano-drug delivery system AV‑NP. The AV‑NP prepared by the present invention has a small size and reduction response characteristics, specifically responds to release drugs in cancer cells, and has good biocompatibility; and the preparation method is green, simple, and efficient, achieving the co-delivery of cytarabine and venetoclax, providing a new idea for chemotherapy of leukemia.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.

The invention relates to the technical field of biological medicines, and provides application of a BCAA inhibitor in preparation of medicines for inhibiting, preventing, relieving or treating mutant leukemia aiming at the problems of high drug resistance, high recurrence rate and limited treatment effect in treatment of DNMT3A mutant AML patients at present. The BCAA inhibitor is gabapentin and / or cytarabine arabinoside. Experiments prove that gabapentin has a treatment effect on DNMT3A mutated acute myelogenous leukemia, meanwhile, it is found that DNMT3A mutated acute myelogenous leukemia cells have drug resistance to cytarabine, and the gabapentin and the cytarabine are combined to have a synergistic effect on the DNMT3A mutated acute myelogenous leukemia. The discovery of the application provides a new thought and direction for treatment of mutant leukemia, especially acute myelogenous leukemia with DNMT3A mutation.

This invention relates to the field of pharmaceutical application technology, specifically a method for preparing and applying a vincristine derivative-antibody conjugate. It involves a composition of a small molecule compound represented by general formula (I), a linker (L), and an antibody (Ab), wherein the small molecule compound is a vincristine derivative, which is conjugated to a targeting antibody via the linker to form an ADC drug with significant antitumor activity. Experiments show that this type of ADC exhibits excellent therapeutic effects in a mouse model of acute myeloid leukemia (AML), with efficacy significantly superior to first-line clinical treatment regimens (such as cytarabine combined with veneclade) and traditional vincristine monotherapy. The ADC provided by this invention has the characteristics of high targeting and low toxicity, providing a new candidate drug for the treatment of malignant tumors such as AML, and possesses significant clinical development value.

The invention provides application of FSP1 as a prognostic marker or a therapeutic target of non-early precursor T acute lymphocytic leukemia (non-ETP ALL), and belongs to the technical field of biological medicine. The invention discovers that the high expression of the coding gene AIFM2 of the FSP1 protein prompts that the non-ETP ALL patient is poor in prognosis. The FSP1 is used as a therapeutic target, and the FSP1 inhibitor not only can remarkably kill non-ETP ALL cells, but also can synergistically increase the sensitivity of the non-ETP ALL cells to small-dose cytarabine (Ara-C). In addition, the FSP1 inhibitor is combined with a small dose of Ara-C, so that the infiltration proportion of non-ETP ALL cells in the spleen and bone marrow of the mouse can be obviously reduced. The AIFM2 gene and the FSP1 protein coded by the AIFM2 gene are expected to become a prognostic marker and a therapeutic target of non-ETP ALL.